The 14-shot weekly dosage currently required by type II diabetics may be about to change according to a Toronto based researcher. The new class of drug is a long-acting mimic of a naturally occurring hormone. In a study to be published in Lancet, 75% of patients in the clinical trial managed to get their diabetes under control with once a week injections. Fewer side effects and some actual benefits were seen.
You can read the full story in the Toronto New.Net